Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence release_pvvx34ylknc3rjihxscxxfhm4q

by R.A. Wells, B. Leber, N.Y. Zhu, J.M. Storring

Published in Current Oncology by MultiMed Inc..

2013   Volume 21, Issue 1, p44


Myelodysplastic syndromes (mdss) constitute a heterogeneous group of malignant hematologic disorders characterized by marrow dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, and pronounced risk of progression to acute myeloid leukemia. Azacitidine has emerged as an important treatment option and is recommended by the Canadian Consortium on Evidence-Based Care in mds as a first-line therapy for intermediate-2 and high-risk patients not eligible for allogeneic stem cell transplant; however, practical guidance on how to manage patients through treatment is limited. This best practice guideline provides recommendations by a panel of experts from Canadian centres of excellence on the selection and clinical management of mds patients with azacitidine. Familiarity with the referral process, treatment protocols, dose scheduling, treatment expectations, response monitoring, management of treatment breaks and adverse events, and multidisciplinary strategies for patient support will improve the opportunity for optimizing treatment outcomes with azacitidine.
In text/plain format

Archived Files and Locations

application/pdf  1.4 MB
web.archive.org (webarchive)
www.current-oncology.com (web)
Read Archived PDF
Type  article-journal
Stage   published
Date   2013-11-07
Language   en ?
DOI  10.3747/co.21.1871
PubMed  24523604
PMC  PMC3921030
Wikidata  Q37577651
Container Metadata
Open Access Publication
In Keepers Registery
ISSN-L:  1198-0052
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: c68cff45-b198-4086-b430-9501a0d9791d